NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

Not Yet RecruitingPhase 1

Sponsor: Eli Lilly and Company

Conditions: Diabetes Mellitus, Type 1, Overweight, Obesity

Interventions: Tirzepatide, Acetaminophen, Placebo

Countries: United States

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity. Participation in this study will last about 8 weeks, including screening and follow-up.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
* Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
* Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening

Exclusion Criteria:

* Participants who have a known clinically significant gastric emptying abnormality
* Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
* Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists

Locations (1)

Miami, Florida, United States